MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000549947

Медицинская библиотека · Oncology research and treatment · 2025

Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115).

Klinghammer Konrad, Graeven Ullrich, Ivanyi Philipp, Dietz Andreas, Hahn Dennis, Hackenberg Stephan, Kasper Stefan, Haderlein Marlen, Pink Daniel, Tinhofer Ingeborg, Schaaf Marina, Sookthai Disorn, Grünwald Viktor

СтатьяКлиническое исследование II фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Elderly, frail, or cisplatin-ineligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. To date, no standard of care has been defined for this population.

METHODS

The randomized, open-label phase 2 study was conducted to determine whether first-line treatment with pembrolizumab (PEM) is superior to methotrexate (MTX) in elderly, frail, or cisplatin-ineligible patients with R/M HNSCC not amenable to local therapies. Patients were randomized 1:1 to receive PEM 200 mg q3w or MTX 40 mg/m2 IV weekly until disease progression or unacceptable toxicity. The primary end point was overall survival after 1 year (1YOS); secondary endpoints were time to failure of strategy (TTFS) at 1 year, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

RESULTS

Of 100 planned participants, 47 (23 in the PEM and 24 in the MTX group) were enrolled. The trial was terminated prematurely. Efficacy did not differ between the treatment arms (1YOS 17.4% for PEM vs. 37.5% for MTX [p = 0.12]). ORR was 17.4% with PEM vs. 12.5% with MTX (p = 0.70), TTFS at 1 year was 91% vs. 100% (p = 0.47), median PFS was 1.8 vs. 2.7 months (p = 0.83), and median OS was 6.1 vs. 9.7 months (p = 0.50), respectively. PD-L1 expression did not impact primary and secondary endpoints. Safety parameters favored PEM.

CONCLUSION

ELDORANDO failed to demonstrate benefit of PEM over MTX regarding 1YOS, ORR, PFS, or OS. The optimal treatment strategy for fragile patients remains to be determined.

Для цитирования: Klinghammer Konrad, Graeven Ullrich, Ivanyi Philipp, Dietz Andreas, Hahn Dennis, Hackenberg Stephan, Kasper Stefan, Haderlein Marlen, Pink Daniel, Tinhofer Ingeborg, Schaaf Marina, Sookthai Disorn, Grünwald Viktor. Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115).. Oncology research and treatment. 2025. DOI: 10.1159/000549947.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.